相关实验视频

Updated: Jan 7, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

脂蛋白的预后值 (a) 在一次性预防的门诊队列中

Netanel Golan¹, Ophir Freund², Tamar Itach¹

¹Division of Cardiology, Faculty of Medical & Health Sciences, Tel-Aviv Sourasky Medical Center, Tel Aviv University, 6 Weizman Street, Tel Aviv, Israel.

Clinical research in cardiology : official journal of the German Cardiac Society

|December 16, 2025

概括

脂蛋白 (Lp) 是心血管事件的强烈预测因素,即使在健康个体中也是如此. 测量Lp (a) 可以改善风险评估,并指导动脉样硬化心血管疾病的向治疗.

科学领域:

心脏病学心脏病学
生物标志物发现发现
预防医学预防医学

背景情况:

脂蛋白 (Lp) 是一种用于动脉样硬化心血管疾病 (ASCVD) 预测的新兴生物标志物.
目前的证据不足以用于例行初级预防查.
高的Lp (a) 水平与心血管风险增加有关.

研究的目的:

评估Lp(a) 在常规查中对心血管风险预测的预后效用.
为了确定一个最佳的Lp(a) 值来预测主要的不良心血管事件 (MACE).
评估Lp (a) 绩效与SCORE2和PCE等现有风险评分相结合.

主要方法:

对3052名成年人进行了回顾性队列研究,从2008年到2024年进行Lp (a) 测量.
主要结局:主要不良心血管事件 (MACE).
使用Spline曲线分析和Cox回归模型来确定Lp (a) 值和预后值,并对共变量进行调整.

主要成果:

一个Lp(a) 值为50mg/dL发现MACE风险增加.
升高的Lp(a) (>50 mg/dL) 独立预测MACE (HR 1.55) 并在调整临床或实验室数据时保持显著.
纳入Lp (a) 改善了SCORE2和PCE风险评分的表现,特别是在高风险人群中.

结论:

在一个大,主要是健康的队列中,Lp (a) 显示出对心血管事件的显著预测价值.
这些发现支持将Lp (a) 测试纳入初级心血管风险评估.
在指导ASCVD新兴向治疗方面,Lp (a) 可能发挥作用.

关键词:

在ASCVD风险模型 (PCE) 中.动脉样硬化心血管疾病.心血管风险评估心血管风险评估脂蛋白 (a) 是一种蛋白质主要预防主要预防.这就是Score2的原因.

更多相关视频

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...